NCT01037855

Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Celtura

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 4,028 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 6 Months
• Healthy volunteers: Accepted

Summary

This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and older.

Conditions

• Novel Influenza A (H1N1)
• A New Flu Virus of Swine Origin

Interventions

Type	Name	Description
OTHER	Non-intervention observational study	Non-intervention observational study

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-06-01
• Completion: 2011-01-01
• First posted: 2009-12-23
• Last updated: 2017-03-14

Locations

10 sites across 4 countries: Chile, Colombia, Germany, Switzerland